

April 22, 2008

Company Name: Hitachi Cable, Ltd.
President: Norio Sato
Listings: First Section, Tokyo Stock Exchange, Inc.
First Section, Osaka Securities Exchange Co., Ltd.
Code Number: 5812
Contact: Shoichi Kogure,
General Manager, Administration Dept.,
Human Resources & Administration Group
TEL: +81-3-6381-1050

Notice Concerning Acquisition of Controlling Interest in European Manufacturer of Ultrasound Probe Cables for Medical Use

We wish to inform you that Hitachi Cable, Ltd. will acquire shares in Astral Meditech GmbH (hereinafter referred to as “Astral Meditech”), a manufacturer of ultrasound probe cables with headquarters located in Traun, Austria, with intentions to make the company a Group subsidiary.

In addition, plans call for the name of Astral Meditech to be changed to Hitachi Cable Austria GmbH at the same time Hitachi Cable acquires these shares in the company.

This acquisition is expected to increase Hitachi Cable Group sales of ultrasound probe cables from approximately 3 billion yen (in FY 2007) to 7 billion yen (in FY 2009).

1. Reasons for and objectives of the acquisition

The Hitachi Cable Group is currently making efforts to expand its electronic wires operations, with particular focus on becoming the world’s largest seller of probe cables for diagnostic ultrasonic devices. Achieving this goal will require bolstering engineering and solutions delivery functions in Europe, a major product development base for our customers.

Astral Meditech is well regarded by its customers, major manufacturers of medical devices, for its advanced design and technological capabilities and for the mobile production capabilities it has achieved together with Akutron LLC, its Ukraine-based manufacturing plants.

This acquisition of stock in Astral Meditech not only will provide the Hitachi Cable Group with superb product-development and manufacturing facilities in Europe in the area of probe cables for use in ultrasonic diagnostic equipment but also will improve the Group’s design capabilities in circuits, metal parts, and plastic parts. In addition, the Hitachi Cable Group intends to use Astral Meditech’s sales channels to major medical-device manufacturers to expand its business, utilizing Astral Meditech as a base for sales of Group products in Europe.

The Hitachi Cable Group intends to leverage its purchase of Astral Meditech to expand sales to world-class medical-device manufacturers, seeking to achieve annual sales of 10 billion yen and a world-leading market share of more than 40% in probe cables for use in ultrasonic diagnostic equipment.

*Figures for market shares in this document are estimates provided by Hitachi Cable.

2. New subsidiary profiles

(1) Astral Meditech (as of January 31, 2008)

(a) Name	: Astral Meditech GmbH
(b) Representative	: Gerald Karoliny
(c) Head office	: Traun, Austria
(d) Year of founding	: 2007
	(Spin-off of the “medical- technology”-unit of ASTRAL Handelsgesellschaft mbH established in 1992)
(e) Primary areas of operations	: Development, production and distribution of products of ultrasound probe cables and other products in the field of medical technology
(f) Fiscal year ends	: January 31
(g) Number of employees	: 39
(h) Total assets	: 4 million EUR
(i) Capital	: 35 thousand EUR
(j) Net sales	: 14 million EUR
(k) Major shareholders and shareholding percentages	: Gerald Karoliny 82.5%, Anneliese Reisenberger-Hagmayer 17.5%

(2) Akutron(as of December 31, 2007)

(a) Name	: Akutron LLC
(b) Representative	: Oksana Raiskaya
(c) Head office	: Kiev, Ukraine
(d) Year of founding	: 2004
(e) Primary areas of operations	: Production of products of ultrasound probe cables and other products in the field of medical technology
(f) Fiscal year ends	: December 31
(g) Number of employees	: 148
(h) Total assets	: 1,776 thousand US dollars
(i) Capital	: 4 thousands US dollars
(j) Major shareholders and shareholding percentages	: Gerald Karoliny 80%、Others 20%

3. Sellers of shares in Astral Meditech

- (a) Name : Gerald Karoliny, Anneliese Reisenberger-Hagmayer
(b) Relationship to Hitachi Cable : No capital or personal relationship, or transaction relationship other than this transaction

4. Holdings in shares of Astral Meditech stock

- (a) Before : 0% of stock held; 0% of voting rights held
(b) After : 70% of stock held; 70% of voting rights held

5. Schedule

Transfer of shares of Astral Meditech stock: mid-June 2008 (planned)

Notes

The forecasts of business performance and other statements regarding the future in this document are based on information obtained by the Company as of the time of preparation of this document and upon certain assumptions deemed reasonable. Due to various factors, actual business performance and other results may vary significantly from these forecasts.